What's in a name? What constitutes the clinical diagnosis of osteoporosis?

Osteoporosis International

Volumn 23, Issue 8, 2012, Pages 2093-2097

  Siris, E S ^a   Boonen, S ^b   Mitchell, P J ^c   Bilezikian, J ^a   Silverman, S ^d  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF DERBY   (United Kingdom)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Bone mineral density; Fracture risk; Fractures; FRAX; Osteoporosis diagnosis

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; CLODRONIC ACID; DENOSUMAB; RALOXIFENE; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE STRENGTH; CLINICAL ASSESSMENT; DIAGNOSIS; DOCUMENTATION; DRUG EFFECT; FEMUR NECK; HEALTH CARE POLICY; HIGH RISK PATIENT; HIP; HIP FRACTURE; HUMAN; LONGITUDINAL STUDY; OSTEOPOROSIS; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; RISK; SPINE; VERTEBRA FRACTURE;

ABSORPTIOMETRY, PHOTON; ALGORITHMS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HIP; HUMANS; MALE; MODELS, BIOLOGICAL; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT; RISK FACTORS; SPINE; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 84864874370     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-1991-0     Document Type: Article

References (25)

1. Klibanski A, Adams-Campbell L, Bassford T et al (2001) NIH consensus development panel on osteoporosis prevention, diagnosis and treatment. Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795
2. Siris ES, Chen Y, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108-1112
3. Schuit SCE, van der Klift M, Weel AEAM et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195-202
4. Wainwright SA, Marshall LM, Ensrud KE et al (2005) Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 90:2787-2793
5. Kanis J (2008) Assessment of osteoporosis at the primary healthcare level. WHO Collaborating Centre, University of Sheffield, Sheffield
6. National Osteoporosis Foundation (2010) Clinician's guide to prevention and treatment of osteoporosis. http://www.nof.org/professionals/clinical- guidelines. Accessed 12 Apr 2012
7. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437-447
8. Lindsay R, Silverman SL, Cooper C et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320-323
9. Gehlbach S, Saag KG, Adachi JD et al (2012) Previous fractures at multiple sites increase the risk for subsequent fractures: the global longitudinal study of osteoporosis in women. J Bone Miner Res 27:645-653
10. Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA (2007) Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Rel Res 461:226-230
11. US Department of Health and Human Services (2004) Bone health and osteoporosis: a report of the surgeon general. http://www. surgeongeneral.gov/ library/bonehealth/content.html. Accessed 12 Apr 2012
12. Dawson-Hughes B, Looker AC, Tosteson ANA, Johansson H, Kanis JA, Melton LJ III (2012) The potential impact of the national osteoporosis foundation guidance on treatment eligibility in theUSA: an update in NHANES 2005-2008. Osteoporos Int 23:811-820
13. Eisman J, Clapham S, Kehoe L (2004) Osteoporosis prevalence and levels of treatment in primary care: the Australian Bone Care Study. J Bone Miner Res 19:1969-1975
14. Marsh D, Akesson K, Beaton DE et al (2011) Coordinator based systems for secondary prevention in fragility fracture patients. Osteoporos Int 22:2051-2065
15. BlackDM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for the treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822
16. Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809
17. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
18. Ryder KM, Cummings SR, Palermo L et al (2008) Does a history of non-vertebral fracture identify women with osteoporosis for treatment? J Gen Intern Med 23:1177-1181
19. Siris ES, Simon JA, Barton IP, McClung MR, Grauer A (2008) Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos Int 19:681-686
20. Kanis JA, Johnell O, Black DM et al (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of raloxifene evaluation trial. Bone 33:293-300
21. McCloskey EV, Johansson H, Oden A et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy-additional results from a double-blind, placebocontrolled randomised study. Osteoporos Int 20:811-817
22. Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049-1054
23. McCloskey EV, Johansson H, Oden A et al (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res. doi:10.1002/jbmr.1606
24. Kanis JA, Johansson H, Oden A, McCloskey EV (2010) A metaanalysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 47:729-735
25. Donaldson MG, Palermo L, Ensrud K, Hochberg MC, Schousboe JT, Cummings SR (2012) Effect of alendronate for reducing fracture by FRAX Score and femoral neck BMD: The fracture Intervention Trial. J Bone Miner Res. doi:10.1002/jbmr.1625